Cathepsin B gene deletion and cysteine protease inhibition are effective in a traumatic brain injury model

Mark Kindy,Jin Yu,Michael Pierschbacher,Nancy Sipes,Greg Hook

DOI: https://doi.org/10.1016/j.jalz.2012.05.1568

2012-01-01

Alzheimer s & Dementia

Abstract:Data suggest that the there are common pathological mechanisms in neurodegeneration caused by Alzheimer's disease (AD) and by traumatic brain injury (TBI). For example, both AD and TBI result in elevated brain activity of the cysteine potease, cathepsin B (CatB). To explore further the commonality of CatB activity in AD and TBI pathology, we extended our previous studies, which showed that CatB is an AD drug target and that cysteine protease inhibitors are effective AD treatments, by studying the effects of deleting the CatB gene or treatment with a cysteine protease inhibitor in a TBI animal model on behavior and pathology. An open skull, single traumatic injury model of TBI was used. Briefly, mice were anesthetized, the skin retracted, the skullcap removed without dura disruption and the cortex injured using the controlled cortical impact device. The skullcap was then replaced and the skin sutured together. CatB gene knockout mice were generated and treated and compared to sufficient CatB treated and sham animals. Treated animals received one dose of the cysteine protease inhibitor, E64d, by gavage immediately post treatment and compared to vehicle treated and sham animals. Motor skills were assessed over seven days using a Rotor-Rod system after which the animals were sacrificed and the CA3 hippocampal neuron density and lesion volume determined by histology and brain CatB activity determined using a fluorometric activity assay. The CatB gene knockout and E64d treated animals had significantly improved motor skills, increased neuron densities and reduced lesion volumes relative to CatB sufficient and vehicle treated animals, respectively. Brain CatB activity was significantly increased relative to sham animals in the CatB sufficient and vehicle treated animals and abolished in CatB deficient and significantly reduced in E64d treated animals. The results validate CatB as a drug target for TBI and demonstrate that a cysteine protease inhibitor is an effective TBI treatment. The data support the hypothesis that increased CatB activity is a common pathology in both AD and TBI.